Medicure (MPH) Stock Overview
A biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
MPH Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Medicure Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.05 |
| 52 Week High | CA$1.27 |
| 52 Week Low | CA$0.63 |
| Beta | 0.91 |
| 1 Month Change | -12.50% |
| 3 Month Change | -0.94% |
| 1 Year Change | 3.96% |
| 3 Year Change | 1.94% |
| 5 Year Change | 0% |
| Change since IPO | -90.28% |
Recent News & Updates
There's No Escaping Medicure Inc.'s (CVE:MPH) Muted Revenues Despite A 26% Share Price Rise
Jun 21
This Is Why Shareholders May Want To Hold Back On A Pay Rise For Medicure Inc.'s (CVE:MPH) CEO
May 14Medicure Inc. (CVE:MPH) Stock Catapults 28% Though Its Price And Business Still Lag The Industry
May 07Recent updates
There's No Escaping Medicure Inc.'s (CVE:MPH) Muted Revenues Despite A 26% Share Price Rise
Jun 21This Is Why Shareholders May Want To Hold Back On A Pay Rise For Medicure Inc.'s (CVE:MPH) CEO
May 14Medicure Inc. (CVE:MPH) Stock Catapults 28% Though Its Price And Business Still Lag The Industry
May 07Medicure Inc.'s (CVE:MPH) Shares Lagging The Industry But So Is The Business
Mar 12Medicure Inc.'s (CVE:MPH) Price Is Right But Growth Is Lacking
Jul 31Estimating The Fair Value Of Medicure Inc. (CVE:MPH)
May 14Investors Don't See Light At End Of Medicure Inc.'s (CVE:MPH) Tunnel
Mar 08We Ran A Stock Scan For Earnings Growth And Medicure (CVE:MPH) Passed With Ease
Aug 28Medicure's (CVE:MPH) Earnings Are Weaker Than They Seem
Nov 30Here's Why Shareholders Should Examine Medicure Inc.'s (CVE:MPH) CEO Compensation Package More Closely
Jun 15Shareholder Returns
| MPH | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 0% | -0.3% | 1.6% |
| 1Y | 4.0% | 12.0% | 18.3% |
Return vs Industry: MPH underperformed the Canadian Biotechs industry which returned 12% over the past year.
Return vs Market: MPH underperformed the Canadian Market which returned 18.3% over the past year.
Price Volatility
| MPH volatility | |
|---|---|
| MPH Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in CA Market | 18.4% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: MPH's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: Insufficient data to determine MPH's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | n/a | Albert Friesen | www.medicure.com |
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia.
Medicure Inc. Fundamentals Summary
| MPH fundamental statistics | |
|---|---|
| Market cap | CA$10.96m |
| Earnings (TTM) | -CA$1.35m |
| Revenue (TTM) | CA$23.20m |
Is MPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MPH income statement (TTM) | |
|---|---|
| Revenue | CA$23.20m |
| Cost of Revenue | CA$10.41m |
| Gross Profit | CA$12.79m |
| Other Expenses | CA$14.15m |
| Earnings | -CA$1.35m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.13 |
| Gross Margin | 55.14% |
| Net Profit Margin | -5.83% |
| Debt/Equity Ratio | 0% |
How did MPH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/25 19:19 |
| End of Day Share Price | 2025/08/22 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Medicure Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Daniel Pearlstein | M Partners Inc. |
| Andre Uddin | Research Capital Corporation |
| Robert Gibson | Ventum Financial Corp |